Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 3/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310398 | 0.69 | HTR5A (0.57) | HTR5ABRD4CREBBPALOX15HSD17B10 | |
| SCHEMBL20635638 | 0.68 | DRD4 (0.48) | HTR5AALOX15HSD17B10DRD4GAA | |
| SCHEMBL21396899 | 0.66 | HTR5A (0.45) | HTR5ABRD4CREBBPALOX15HSD17B10 | |
| SCHEMBL7337375 | 0.65 | HTR5A (0.47) | HTR5AALOX15HSD17B10GAANPSR1 | |
| SCHEMBL1828551 | 0.64 | — | — | |
| SCHEMBL2041999 | 0.64 | — | — | |
| SCHEMBL30668800 | 0.64 | — | — | |
| SCHEMBL11441092 | 0.64 | HTR5A (0.55) | HTR5ABRD4CREBBPALOX15HSD17B10 | |
| SCHEMBL22686239 | 0.64 | MB (0.42) | GAA | |
| SCHEMBL44824 | 0.63 | HTR5A (0.53) | HTR5ABRD4CREBBPALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11033555-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | Kinoxis Therapeutics Pty Ltd (AU) | 2021-06-15 | — | — | US | disclosed |
| US-20190290658-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | Kinoxis Therapeutics Pty Ltd (AU) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290658-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | SLC18A2, SLC6A3, CES2 | HTR5A 76/4885BRD4 2734/4885CREBBP 1079/4885 |
| US-11033555-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | SLC18A2, SLC6A3, CES2 | HTR5A 76/4885BRD4 2734/4885CREBBP 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.